Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,015.00    -10.00 (-0.17%)
Bid:
6,005.00
Ask:
6,010.00
Spread: 5.00 (0.083%)
Market Cap: £5.14b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Interim Management Statement

12 Jul 2019 07:00

RNS Number : 3003F
DCC PLC
12 July 2019
 

 

 

12 July 2019

 

DCC plc

 

Interim Management Statement

 

Good Growth in First Quarter Operating Profit and Guidance for the Year Reiterated

 

DCC plc, the leading international sales, marketing and support services group, is issuing this Interim Management Statement in advance of the Company's AGM to be held in Dublin at 11.00 am today.

 

First quarter ended 30 June 2019

DCC traded in line with expectations and delivered good growth in Group operating profit for the first quarter ended 30 June 2019, driven by acquisitions completed in the prior year.

 

Year ending 31 March 2020

DCC's profits are significantly weighted towards the second half of its financial year. At what is still a very early stage in the financial year, the Group reiterates its belief that the year ending 31 March 2020 will be another year of profit growth and development.

 

Development activity

DCC Technology recently completed the acquisitions of Comm-Tec in Germany and Amacom in the Netherlands, following receipt of customary regulatory approvals. Both Comm-Tec and Amacom will significantly enhance DCC Technology's service offering in Continental Europe and will strengthen its relationships with suppliers and customers in the region.

 

DCC Retail & Oil also recently finalised the creation of a new branded aviation fuels marketing and distribution business in Denmark with Shell Aviation, which involved Shell Aviation purchasing an interest in DCC's existing Danish aviation fuels business.

 

Further detail regarding each of the above transactions is included in DCC's Development Update announcement of 14 May 2019.

 

DCC has grown substantially in recent years and now has significant operations across 18 countries, with market-leading positions in each of its LPG, Retail & Oil, Technology and Healthcare divisions. DCC's ambition and capacity for further development, together with the Group's leading market positions and increased geographic reach, provide substantial opportunity for the continued growth and development of the business.

 

Disposal

DCC Vital recently entered into an agreement to dispose of its UK generic pharma activities and related manufacturing facility in Ireland (Kent Pharma and Athlone Laboratories), subject to regulatory and other consents. The disposal will sharpen the strategic focus of DCC Vital, allowing it to concentrate on those areas where it has market leading positions and sustainable competitive advantage, in particular in the sales, marketing and distribution of medical products in Britain and Ireland. DCC Vital will also continue to develop its pharma activities in Ireland which encompass a market leadership position in the procurement and sales of Exempt Medicinal Products and agency distribution into the hospital and retail pharmacy segments.

 

 

Forthcoming events

DCC expects to announce its interim results for the six months ending 30 September 2019 on Tuesday 12 November 2019.

 

For reference:

Donal Murphy, Chief Executive

Fergal O'Dwyer, Chief Financial Officer

Kevin Lucey, Head of Capital Markets

 

Telephone: +353 1 2799 400

Email: investorrelations@dcc.ie

Web: www.dcc.ie

 

Powerscourt (Media)

Lisa Kavanagh / Victoria Palmer-Moore

Telephone: +44 20 7250 1446

Email: DCC@powerscourtgroup.com

 

 

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on performance and growth. It operates through four divisions: LPG, Retail & Oil, Technology and Healthcare.

 

DCC is an ambitious and entrepreneurial business operating in 18 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

 

Headquartered in Dublin, employing approximately 12,700 people, DCC's four divisions are:

· DCC LPG - a leading LPG sales and marketing business with operations in Europe, the US and Asia and a developing business in the retailing of natural gas and electricity;

· DCC Retail & Oil - a leader in the sales, marketing and retailing of transport and commercial fuels, heating oils and related products and services in Europe;

· DCC Technology - a leading route-to-market and supply chain partner for global technology brands and customers; and

· DCC Healthcare - a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners.

 

DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2019, DCC generated revenue of £15.2 billion and operating profit of £460.5 million.

 

DCC has an excellent record, delivering compound annual growth of 14.6% in operating profit and generating an average return on capital employed of approximately 19% over 25 years as a public company.

 

Forward-looking statements

This announcement contains some forward-looking statements that represent DCC's expectations for its business, based on current expectations about future events, which by their nature involve risk and uncertainty. DCC believes that its expectations and assumptions with respect to these forward-looking statements are reasonable, however because they involve risk and uncertainty as to future circumstances, which are in many cases beyond DCC's control, actual results or performance may differ materially from those expressed in or implied by such forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTQFLFFKDFLBBZ
Date   Source Headline
14th Jul 20202:28 pmRNSHolding in Company TR-1
8th Jul 202011:38 amRNSHolding in Company TR-1
24th Jun 20209:39 amRNSHolding in Company TR-1
18th Jun 202012:25 pmRNS2020 Annual Report, Notice of AGM and Proxy Form
3rd Jun 202010:10 amRNSHolding in Company TR-1
29th May 202011:27 amRNSTotal Voting Rights
28th May 20206:21 pmRNSDirector/PDMR Shareholding
28th May 20201:02 pmRNSHolding in Company TR-1
19th May 20205:04 pmRNSBoard Changes
19th May 20207:00 amRNSResults for the year ended 31 March 2020
14th May 20203:30 pmRNSHolding in Company TR-1
27th Apr 20206:02 pmRNSDisclosure of Rights Attached to Equity Shares
16th Apr 20204:24 pmRNSDirector Declaration
9th Apr 20204:21 pmRNSHolding in Company TR-1
3rd Apr 20204:01 pmRNSHolding in Company TR-1
25th Mar 20203:22 pmRNSHolding in Company TR-1
25th Mar 20207:00 amRNSDCC Healthcare announces acquisition of Amerilab
19th Mar 20204:10 pmRNSHolding in Company TR-1
19th Mar 20209:46 amRNSHolding in Company TR-1
18th Mar 202012:14 pmRNSHolding in Company TR-1
6th Mar 20204:08 pmRNSHolding in Company TR-1
28th Feb 202010:54 amRNSTotal Voting Rights
24th Feb 20208:38 amRNSBoard Change
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1
4th Feb 20207:00 amRNSInterim Management Statement
17th Jan 20209:23 amRNSHolding in Company TR-1
3rd Jan 202010:03 amRNSHolding in Company - TR1
23rd Dec 201912:44 pmRNSHolding in Company TR-1
5th Dec 20195:44 pmRNSHolding in Company - TR1
29th Nov 20191:39 pmRNSTotal Voting Rights
27th Nov 20199:18 amRNSDirector Declaration
18th Nov 20196:14 pmRNSDirector/PDMR Shareholding
12th Nov 20197:00 amRNSResults for the six months ended 30 September 2019
12th Nov 20197:00 amRNSDCC Healthcare acquires Ion Laboratories
7th Nov 201911:30 amRNSHolding in Company TR-1
23rd Oct 20192:25 pmRNSHolding in Company TR-1
21st Oct 20195:01 pmRNSHolding in Company TR-1
18th Oct 20194:46 pmRNSHolding in Company TR-1
17th Oct 20199:43 amRNSHolding in Company TR-1
25th Sep 20195:39 pmRNSHolding in Company TR-1
4th Sep 20199:57 amRNSHolding in Company TR-1
9th Aug 201910:42 amRNSHolding in Company TR-1
7th Aug 20199:23 amRNSHolding in Company TR-1
31st Jul 20192:58 pmRNSTotal Voting Rights
16th Jul 20196:14 pmRNSDirector/PDMR Shareholding
12th Jul 20193:06 pmRNSResult of AGM
12th Jul 20197:00 amRNSInterim Management Statement
5th Jul 20199:06 amRNSHolding in Company TR-1
19th Jun 20199:22 amRNSHolding in Company TR-1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.